Completed PHASE3 INTERVENTIONAL 2-arm NCT01991821

European Phase III Study of APD421 in PONV

Randomised, Double-blind, Placebo-controlled Phase III Study of APD421 (Amisulpride for IV Injection) as Prophylaxis Against Post-operative Nausea and Vomiting

Sponsor: Acacia Pharma Ltd

Conditions PONV

Interventions APD421 Placebo

Updated 9 times since 2017 Last updated: Aug 9, 2019 Started: Jul 31, 2013 Primary completion: Jan 31, 2014 Completion: Jan 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on PONV, this trial is completed. The trial is conducted by Acacia Pharma Ltd and has accumulated 9 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2023 — Jul 2024 [monthly]

Completed PHASE3
Dec 2022 — Jan 2023 [monthly]

Completed PHASE3
Dec 2021 — Dec 2022 [monthly]

Completed PHASE3

▶ Show 4 earlier versions

Jan 2021 — Dec 2021 [monthly]

Completed PHASE3
Sep 2019 — Jan 2021 [monthly]

Completed PHASE3
Jun 2018 — Sep 2019 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jul 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Acacia Pharma Ltd

Data source: Acacia Pharma Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Strasbourg, France
• Würzburg, Germany